Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PHILLIP FYMAN AND ALEXANDER WEINGARTEN MD PC

NPI: 1457841967 · SYOSSET, NY 11791 · Clinical Medical Laboratory · NPI assigned 05/10/2018

$22K
Total Medicaid Paid
2,031
Total Claims
1,922
Beneficiaries
3
Codes Billed
2019-02
First Month
2020-12
Last Month

Provider Details

Authorized OfficialFYMAN, PHILLIP (PRESIDENT)
Parent OrganizationPHILLIP FYMAN AND ALEXANDER WEINGARTEN MD PC
NPI Enumeration Date05/10/2018

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 1,188 $12K
2020 843 $10K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,079 1,024 $21K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 936 882 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 16 16 $79.50